Zydus Lifesciences arm application for Menkes disease treatment gets USFDA priority review Ruchika Sharma7 Jan 2025 2:00 PM ISTSolana Beach: Sentynl Therapeutics, Inc., a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd., and Fortress Biotech,...
Sentynl Therapeutics, a Zydus company acquires Zokinvy for Progeria from Eiger Biopharma Ruchika Sharma5 May 2024 12:00 PM ISTAhmedabad: Sentynl Therapeutics, Inc., a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences Ltd. (Zydus Group), and Eiger...
Zydus Lifesciences arm gets marketing nod for Nulibry from UK MHRA for MoCD Type A Ruchika Sharma22 April 2024 2:08 PM ISTAhmedabad: Zydus Lifesciences Ltd. has announced that its wholly-owned subsidiary Sentynl Therapeutics, Inc., has received marketing...
Zydus Lifesciences US arm concludes asset transfer of CUTX-101 for Menkes disease from Cyprium Therapeutics Ruchika Sharma6 Dec 2023 1:30 PM ISTSentynl now assumes full responsibility for the development and commercialization of CUTX-101.
Zydus Lifesciences reports 25 percent decline in consolidated net profit at Rs 297 crore in Q4 Ruchika Sharma20 May 2023 10:00 AM ISTNew Delhi: Zydus Lifesciences Ltd on Thursday reported a 25.36 per cent decline in consolidated net profit at Rs 296.6 crore in the fourth quarter...
Zydus Lifesciences US arm, BridgeBio Pharma get European Commission nod for NULIBRY to treat MoCD Type A Ruchika Sharma21 Sept 2022 12:15 PM ISTAhmedabad: Sentynl Therapeutics, Inc., a U.S.-based biopharmaceutical company owned by Zydus Lifesciences Ltd and BridgeBio Pharma, Inc., a...
Zydus Cadila arm Sentynl buys Copper Histidinate product candidate from Cyprium Ruchika Sharma26 Feb 2021 12:00 PM ISTUnder the agreement, Cyprium is eligible to receive up to $20 million in upfront development and regulatory cash milestones through NDA approval, as...
